The BRCA2 p.I605fs*9 deletion, impacting six breast cancers in current study, was predictive of treatment response of PARP (poly ADP ribose polymerase) inhibitors based on the OlympiAD and EMBRCA trials. The gene discussed is BRCA2; the disease is breast carcinoma.